QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, announced that Rodman & Renshaw initiated coverage of the company with a Buy rating and a $8 price target. The research report was led by Michael G. King Jr., director of research and senior biotechnology analyst at Rodman & Renshaw. Quantum BioPharma said the coverage is unpaid and that it provided no consideration or fees for the report. To view the full press release, visit https://ibn.fm/OC9TG About Quantum BioPharma Ltd. Quantum is a biopharmaceutical company dedicated to building a…